Existing jab offers “ray of hope” for preventing rheumatoid arthritis
A drug currently used as a second- or third-line treatment for those with rheumatoid arthritis has shown huge promise as a preventative, stopping the onset of the debilitating disease in 92.8% of at-risk participants after 12 months.Abatacept, a biologic sold as Orencia in the US, is just one of the drugs used by rheumatoid arthritis (RA) sufferers to manage symptoms such as inflammation and swelling, and is given as self-administered weekly stomach/thigh injections via needle or pen, or through intravenous (IV) therapy…